CANCERDIALOGUES.COM
When you have cancer act as if there is no tomorrow, believe you will live forever; focus on your life not on the disease

Daniel Weber M health Sci.

 

Daniel Weber began his study of Oriental Medicine in 1969 in Boston. He studied with J. R. Worsley and J. D. van Buren in the UK from 1974 before receiving his B.Ac. Daniel went to Japan in 1976 and studied with Dr. Masahiro Oki and Dr. Okada. He has been in practice in Sydney Australia since 1977 and created the first English language data base for Chinese herbal medicine in 1992. This data base was awarded 'Innovations in Australian Design' and put on exhibit in the Powerhouse Museum.

Daniel has studied in China from 1988, visiting more than a dozen times with numerous awards and two honorary Ph.Ds as well as being an advisor to Hangzhou TCM Institute in Hangzhou. Daniel has a Master of Health Science (Aust) and is completing his research Doctorate. Daniel is not just an academic but a committed clinician, and continues a clinic as well as his ongoing studies. His research into complimentary cancer treatments and his seminars to practitioners in Australia, South Africa and the US have attracted positive comment from leaders in the field. He is committed to creating a dialogue between all types of health care professionals.

 

Survivin and Resveratrol

 

Sensitisation for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by the chemopreventive agent resveratrol.

 

Fulda S, Debatin KM.

University Children's Hospital, Ulm , Germany .

Survivin is a member of the inhibitor of apoptosis proteins that is expressed at high levels in most human cancers and may facilitate evasion from apoptosis and aberrant mitotic progression. Naturally occurring dietary compounds such as resveratrol have gained considerable attention as cancer chemopreventive agents. Here, we discovered a novel function of the chemopreventive agent resveratrol: resveratrol is a potent sensitizer of tumour cells for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through p53-independent induction of p21 and p21-mediated cell cycle arrest associated with survivin depletion. Concomitant analysis of cell cycle, survivin expression, and apoptosis revealed that resveratrol-induced G(1) arrest was associated with down-regulation of survivin expression and sensitization for TRAIL-induced apoptosis. Accordingly, G(1) arrest using the cell cycle inhibitor mimosine or induced by p21 overexpression reduced survivin expression and sensitized cells for TRAIL treatment. Likewise, resveratrol-mediated cell cycle arrest followed by survivin depletion and sensitization for TRAIL was impaired in p21- deficient cells. Also, down-regulation of survivin using survivin antisense oligonucleotides sensitized cells for TRAIL-induced apoptosis. Importantly, resveratrol sensitized various tumour cell lines, but not normal human fibroblasts, for apoptosis induced by death receptor ligation or anticancer drugs. Thus, this combined sensitizer (resveratrol)/inducer (e.g., TRAIL) strategy may be a novel approach to enhance the efficacy of TRAIL-based therapies in a variety of human cancers.

Cancer Res. 2004 Jan 1;64(1):337-46.